Check out the Detailed Program! Learn More

Exploring aspirin’s role in Barrett’s esophagus care

Barrett’s esophagus develops when chronic gastroesophageal reflux damages the normal lining of the esophagus and causes specialized intestinal-type cells to appear. This condition can increase the risk of esophageal adenocarcinoma, although most people with Barrett’s will never develop cancer. Management usually combines reflux control, surveillance endoscopy, and treatment of precancerous changes when they arise.

Chemoprevention refers to using a medication or compound to reduce the chance that abnormal tissue will progress. Aspirin has attracted interest because it affects inflammation and platelet activity, two biological processes that may contribute to cancer development. Research has examined whether regular aspirin use could add protection for selected people with Barrett’s esophagus.

Why aspirin is being studied

Long-term irritation from acid reflux can create an inflammatory environment in the esophageal lining. Aspirin inhibits cyclooxygenase enzymes involved in prostaglandin production, which may reduce inflammatory signaling. It also influences platelet behavior and pathways associated with abnormal cell growth. These effects provide a scientific rationale for studying aspirin as a preventive therapy.

The idea is not that aspirin reverses Barrett’s tissue or replaces acid suppression. Instead, it has been investigated as a possible additional measure that might lower the risk of high-grade dysplasia or esophageal adenocarcinoma over time. The potential benefit must be weighed against aspirin’s recognized harms, especially gastrointestinal bleeding.

What clinical research has found

The AspECT randomized trial evaluated high- and low-dose proton pump inhibitor therapy, with or without aspirin, in people with Barrett’s esophagus. Its results suggested that high-dose acid suppression offered greater protection against a combined endpoint, while aspirin appeared to provide a smaller additional benefit, particularly when used alongside intensive proton pump inhibition.

These findings are important but require careful interpretation. The study followed participants for years and measured a composite outcome rather than proving that aspirin prevents invasive cancer in every patient. Researchers have also noted questions about dosage, adherence, the balance of benefit and risk, and how the findings should influence routine clinical practice.

Consideration What the evidence suggests Clinical meaning
Possible benefit Aspirin may reduce progression-related outcomes in some patients It remains an individualized option rather than a universal treatment
Acid suppression Proton pump inhibitors are central to reflux management Aspirin should not be viewed as a substitute for prescribed acid control
Main harm Gastrointestinal bleeding and ulcers are established risks Bleeding history and interacting drugs require careful review
Evidence limitations Research does not establish equal benefit for all patients Decisions should reflect age, risk factors, and patient preferences

Benefits must be balanced with bleeding risk

Aspirin can irritate the stomach and duodenum and can impair clot formation. The chance of a serious bleed rises with older age, previous ulcers or bleeding, anticoagulant use, corticosteroids, some anti-inflammatory pain medicines, heavy alcohol use, and certain medical conditions. Even low-dose aspirin is not automatically risk-free.

A proton pump inhibitor may reduce upper gastrointestinal complications, but it cannot eliminate bleeding risk. People should also distinguish between aspirin prescribed for cardiovascular prevention and aspirin considered for Barrett’s esophagus. A cardiovascular indication may change the overall balance, while taking aspirin solely for cancer prevention may offer too little benefit for some individuals.

Who might be considered

There is no single aspirin regimen appropriate for everyone with Barrett’s esophagus. A clinician may consider the extent of Barrett’s tissue, presence or absence of dysplasia, age, cardiovascular risk, family history, smoking status, reflux control, and anticipated bleeding risk. The condition’s progression risk is also influenced by factors such as male sex, obesity, and a long duration of reflux symptoms.

Endoscopic findings remain central to care. Dysplasia may require closer surveillance, endoscopic eradication therapy, or referral to a specialist team. Aspirin should never delay recommended endoscopy or be used as a reason to overlook new symptoms such as difficulty swallowing, vomiting blood, black stools, or unexplained weight loss.

Making the decision within broader care

Aspirin decisions work best as part of a complete management plan. Reflux treatment, weight management where appropriate, tobacco cessation, moderation of alcohol, and adherence to surveillance schedules can all support esophageal health. Nutrition and physical readiness also matter when a person may need an intervention; guidance on nutrition before surgery illustrates how supportive care can complement specialist treatment.

Patients should provide a full medication and supplement list before starting aspirin. This includes anticoagulants, antiplatelet drugs, herbal products, and over-the-counter pain relievers. Any plan should specify the intended dose, monitoring approach, warning symptoms, and circumstances that require stopping or reassessing treatment.

Questions to discuss with a specialist

A focused consultation can turn a broad research question into a personalized risk assessment. Useful points to review include:

  • Whether aspirin has a clear cardiovascular indication in addition to any possible esophageal benefit
  • The individual risk of ulceration, gastrointestinal bleeding, kidney disease, or drug interactions
  • How aspirin would fit with proton pump inhibitor treatment and scheduled endoscopic surveillance
  • Whether dysplasia, extensive Barrett’s tissue, or other findings call for specialist referral
  • Which symptoms should prompt urgent medical attention

Aspirin should be started, continued, or stopped only with appropriate medical guidance. People already taking it for heart or vascular disease should not discontinue it abruptly without speaking with the prescribing clinician.

Evidence from gastroenterology research continues to refine the role of chemoprevention in Barrett’s esophagus. Discuss the potential advantages and harms with a gastroenterologist or qualified healthcare professional, and use that conversation to establish a surveillance and treatment plan suited to your individual risk.

About ISDE

The ISDE is an international, multispecialty society devoted to the study of the esophagus in disease and in health that was founded in 1979. The aims of the ISDE are to promote the exchange of scientific and medical knowledge among specialists in the field, to maintain interchange with organizations and industries, and to encourage basic and clinical research in fields related to the esophagus. In order to promote the professional and educational development of individuals interested in the esophagus, the ISDE sponsors its own journal, international congresses, and other educational programs. The ISDE Secretariat was in Tokyo, Japan, from 1979 to 2004, and then resided in Los Angeles, California, from 2004 through 2010. Since 2010 the Secretariat has been in Vancouver, British Columbia, under the auspices of International Conferences Service, Ltd. The ISDE welcomes participation by existing members and encourages individuals who are professionally interested in the esophagus to become members. Benefits include reduced registration fees at our congresses and other educational offerings, restricted access to website content and member search capability, access to webcasts, reduced subscription rates for our journal, and the opportunity to help lead this organization into a position of leadership in the worldwide medical community.